
Acutus Medical (NASDAQ:AFIB) completed patient enrollment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trial.
The trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter.